Abou-El-Naga, I. F.; Sa, D. E.; Gaafar, M. R.; Ahmed, S. M.; El-Deeb, S. A. published the artcile< A new scope for orlistat: Effect of approved anti-obesity drug against experimental microsporidiosis>, Product Details of C29H53NO5, the main research area is antiobesity drug orlistat microsporidiosis intestine.
As the current therapies for intestinal microsporidiosis are either inconsistent in their efficacies or hampered by several adverse effects, alternative antimicrosporidial agents are being sought. The present study is the first that was designed to evaluate the potency of orlistat, an approved anti-obesity drug, against intestinal microsporidiosis caused by both Enterocytozoon bieneusi and Encephalitozoon intestinalis. Results were assessed through studying fecal and intestinal spore load, intestinal histopathol. changes, viability, and infectivity of spores from treated animals. Results showed that orlistat has promising antimicrosporidia potential, with better results in E. intestinalis than E. bieneusi. The animals that received orlistat showed statistically significant decrease in the fecal and intestinal spore load, when compared to the corresponding control infected nontreated mice. The results were insignificant compared to fumagillin and albendazole. Light microscopic examination of stained intestinal sections revealed amelioration of the pathol. changes and decreased inflammatory cells detected in the control infected nontreated mice. Spores encountered from stool of orlistat-treated E. bieneusi and E. intestinalis mice showed low viability and significant reduction of infectivity vs. their control. Thus, considering the results of the present work, orlistat proved its effectiveness against the intestinal microsporidial infection.
Medical Mycology published new progress about Antiobesity agents. 96829-58-2 belongs to class amides-buliding-blocks, and the molecular formula is C29H53NO5, Product Details of C29H53NO5.
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics